K

Knotus Co Ltd
KOSDAQ:278650

Watchlist Manager
Knotus Co Ltd
KOSDAQ:278650
Watchlist
Price: 2 160 KRW Market Closed
Market Cap: 181.9B KRW
Have any thoughts about
Knotus Co Ltd?
Write Note

Knotus Co Ltd
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Knotus Co Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
K
Knotus Co Ltd
KOSDAQ:278650
Free Cash Flow
â‚©1.2B
CAGR 3-Years
-44%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Free Cash Flow
â‚©960.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Free Cash Flow
-â‚©3.7B
CAGR 3-Years
56%
CAGR 5-Years
35%
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Free Cash Flow
-â‚©4.8B
CAGR 3-Years
8%
CAGR 5-Years
19%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Free Cash Flow
â‚©43.2B
CAGR 3-Years
N/A
CAGR 5-Years
30%
CAGR 10-Years
N/A
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Free Cash Flow
-â‚©535.5m
CAGR 3-Years
69%
CAGR 5-Years
43%
CAGR 10-Years
N/A
No Stocks Found

Knotus Co Ltd
Glance View

Market Cap
181.9B KRW
Industry
Life Sciences Tools & Services

KNOTUS Co. Ltd. engages in the provision of clinical research services. The company is headquartered in Incheon, Incheon. The company went IPO on 2019-11-27. is a Korea-based company principally engaged in the nonclinical experiment business. Along with subsidiaries, the Company operates its business through three segments. The Nonclinical Contract Research Organization (CRO) Business segment conducts nonclinical experiments on new developed substances such as new drugs, and tests the efficacy and pharmacodynamics of the substances. This segment also provides services including new drug development related equipment, software and analysis of experimental results. The Animal Laboratory Construction Business segment is engaged in the construction and design of animal laboratories and the supply of reagent consumables. The Pet Business segment is engaged in the development of animal medicines and the sale of pet supplies.

Intrinsic Value
2 258.02 KRW
Undervaluation 4%
Intrinsic Value
Price
K

See Also

What is Knotus Co Ltd's Free Cash Flow?
Free Cash Flow
1.2B KRW

Based on the financial report for Dec 31, 2023, Knotus Co Ltd's Free Cash Flow amounts to 1.2B KRW.

What is Knotus Co Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
-44%

Over the last year, the Free Cash Flow growth was 181%. The average annual Free Cash Flow growth rates for Knotus Co Ltd have been -44% over the past three years .

Back to Top